Niche market Target a high-need medical device market with acute and chronic lung disease patients where ICU and hospital systems seek advanced ECMO solutions, presenting a clear pain point for clinicians and procurement teams.

Clinical leadership Leverage Dr. Bartley Griffith and the team’s renowned expertise in cardiothoracic surgery and fluid dynamics to establish credibility with hospital decision makers, key opinion leaders, and investors.

Early stage funding Capitalize on the company’s modest revenue and substantial funding to pursue pilot programs, hospital partnerships, and regulatory milestones that can de-risk adoption for early adopters.

Strategic partnerships Position the compact artificial lung as a disruptive ECMO option for tertiary care centers, enabling collaboration with large health systems, academic centers, and specialty clinics to accelerate pilots and scale.

Technology differentiation Highlight the integration of advanced biomechanics, compact device design, and potential workflow improvements to reduce ICU time and improve patient rehabilitation, addressing cost and outcomes concerns for procurement teams.